Phase II study of fixed dose rate Gemcitabine-Oxaliplatin Integrated with concomitant 5FU and 3-D Conformal Radiotherapy for the treatment of localised pancreatic cancer: GOFURTGO.
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2016
At a glance
- Drugs Gemcitabine; Oxaliplatin
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms GOFURTGO
- 15 Dec 2010 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 29 Dec 2009 New trial record